Testosterone and body functions

References

• World Health Organization. Men, ageing and health. Aging Male 2000; 3: 3–36
   Google Scholar
• Kohn F M, Schuppe H C, Schill W B, Elbers J. Treatment of late onset hypogonadism with a new formulation of testosterone undecanoate – baseline data of a multicenter study. Andrologia 2004; 36: 174–175
   Google Scholar
• Devogelaer J P, De Cooman S, Nagant de Deuxchaisnes C. Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas 1992; 15: 17–23
   PubMed Web of Science ®Google Scholar
• Katznelson L, Finkelstein J S, Schoenfeld D A, Rosenthal D I, Anderson E J, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358–4365
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto A M, Snyder P J, Weber T, Berman N, Hull L, Swerdloff R S. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085–2098
   PubMed Web of Science ®Google Scholar
• Benito M, Vasilic B, Wehrli F W, Bunker B, Wald M, Gomberg B, Wright A C, Zemel B, Cucchiara A, Snyder P J. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res 2005; 20: 1785–1791
   PubMed Web of Science ®Google Scholar
• Dean J D, Carnegie C, Rodzvilla J. Long-term effects of Testim 1% testosterone gel in hypogonadal men. Rev Urol 2004; 6(Suppl. 6)S22–S29
   Google Scholar
• Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh A B, Lee M I, Storer T W, Casaburi R, Shen R, Bhasin S. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab 2001; 283: E154–E164
   Google Scholar
• Snyder P J, Peachey H, Hannoush P, Berlin J A, Loh L, Lenrow D A, Holmes J H, Dlewati A, Santanna J, Rosen C J, Strom B L. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647–2653
   PubMed Web of Science ®Google Scholar
• Burris A S, Banks S M, Carter C S, Davidson J M, Sherins R J. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297–304
   PubMedGoogle Scholar
• Sih R, Morley J E, Kaiser F E, Perry H M, 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–1667
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer T W, Berman N, Yarasheski K E, Clevenger B, Phillips J, Lee W P, Bunnell T J, Casaburi R. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407–413
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff R S, Iranmanesh A, Dobs A, Snyder P J, Cunningham G, Matsumoto A M, Weber T, Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839–2853
   PubMed Web of Science ®Google Scholar
• Urban R J, Bodenburg Y H, Gilkison C, Foxworth J, Coggan A R, Wolfe R R, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820–E826
   PubMed Web of Science ®Google Scholar
• Bouloux P. Testim 1% testosterone gel for the treatment of male hypogonadism. Clin Ther 2005; 27: 286–298
   PubMedGoogle Scholar
• McNicholas T A, Dean J D, Mulder H, Carnegie C, Jones N A. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003; 91: 69–74
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Mootha V K, Dwyer A A, Hardin M, Lee H, Eriksson K F, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes F J. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636–1642
   PubMed Web of Science ®Google Scholar
• Rhoden E L, Ribeiro E P, Teloken C, Souto C A. Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 2005; 96: 867–870
   PubMed Web of Science ®Google Scholar
• Tibblin G, Adlerberth A, Lindstedt G, Bjorntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996; 45: 1605–1609
   PubMed Web of Science ®Google Scholar
• Haffner S M, Shaten J, Stern M P, Smith G D, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143: 889–897
   PubMed Web of Science ®Google Scholar
• Stellato R K, Feldman H A, Hamdy O, Horton E S, McKinlay J B. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: 490–494
   PubMed Web of Science ®Google Scholar
• Oh J Y, Barrett-Connor E, Wedick N M, Wingard D L. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55–60
   PubMed Web of Science ®Google Scholar
• Svartberg J, Jenssen T, Sundsfjord J, Jorde R. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromso Study. Diabetes Metab 2004; 30: 29–34
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Boyanov M A, Boneva Z, Christov V G. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1–7
   PubMedGoogle Scholar
• Kohn F M, Ring J, Schill W B. [Dermatologic aspects of male hypogonadism]. Hautarzt 2000; 51: 223–230
   PubMedGoogle Scholar
• O'Connor D B, Archer J, Wu F C. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 2004; 89: 2837–2845
   PubMed Web of Science ®Google Scholar